Methotrexate Orion (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a co‑factor needed for DNA synthesis. By disrupting nucleotide formation, the drug hampers the replication of rapidly dividing cells, including immune cells and cancer cells, thereby reducing inflammation and tumor growth.

The dosage of Methotrexate Orion is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Methotrexate Orion is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended during breastfeeding because the drug can be transferred to the infant through milk.

To request Methotrexate Orion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methotrexate is a folate antagonist, whereas other antimetabolites such as 5‑fluorouracil target thymidylate synthase. Methotrexate’s broad immunosuppressive and antineoplastic effects make it suitable for both autoimmune diseases and certain cancers, while some alternatives may be more disease‑specific or have different toxicity profiles.

Methotrexate Orion should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Methotrexate Orion is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact administration schedule—daily, weekly, or as part of a treatment cycle—depends on the condition being treated and the clinician’s recommendation.

Serious risks include severe liver toxicity, pulmonary fibrosis, and bone‑marrow failure, which can lead to life‑threatening infections or bleeding. Patients should undergo regular monitoring of liver enzymes, lung function, and blood counts to detect these complications early.

Methotrexate Orion should not be used by pregnant individuals, nursing mothers, or patients with severe hepatic or renal impairment unless closely monitored. It is also contraindicated in patients with known hypersensitivity to methotrexate or any of its excipients.